SkinCeuticals Introduces Serum Evaluated on Users of Weight Loss Medication

SkinCeuticals is making a strategic move into the GLP-1 market with the launch of their A.G.E. Interrupter Ultra Serum, priced at $185. This product has been specially formulated for users of GLP-1 weight loss drugs, addressing issues like skin laxity often associated with rapid weight loss. The serum, containing 30% proxylane and 4.6% wild fruit flavonoids, aims to combat glycation and support collagen production.

Rapid weight loss can lead to less hydrated and looser skin, exacerbating fine lines and wrinkles. With predictions that 30 million people in the U.S. might use weight loss drugs by 2030, SkinCeuticals sees a significant opportunity in this market.

Their approach aligns medical aesthetics with topical skin care solutions, a strategy that could appeal to a substantial user base. The company emphasizes the synergy between scientific advances and aesthetic procedures, particularly in the growing channels of GLP-1 prescriptions.

SkinCeuticals’ recent trials showed that the new serum visibly reduced skin laxity in users within four weeks. The ongoing focus on the impact of GLP-1 drugs on skin remains a priority for the brand, as they anticipate continued growth in this segment.